HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Resource use associated with topiramate in migraine prophylaxis.

AbstractPURPOSE:
The effect of topiramate prophylaxis on medication use and medical resource use for migraine patients was studied.
METHODS:
Medical and pharmacy claims from a commercially insured population were analyzed from July 1, 1999, to March 31, 2004. The study sample included patients with at least one physician encounter or facility claim with a diagnosis of migraine at any point during the study's time frame. Patients either were naive to drugs labeled for migraine prophylaxis or had switched to topiramate from another drug labeled for migraine prophylaxis. The date of topiramate initiation was between January 1, 2000, and September 30, 2003; topiramate initiation was the index date. Demographic and clinical characteristics were evaluated. Migraine-related medication use and resource use were compared between the pre- and postindex periods.
RESULTS:
Of the 1749 patients analyzed, 90.2% were female. Neurologists wrote 54% of the index prescriptions. The mean +/- S.D. topiramate dosage was 98 +/- 65 mg/day. Statistically significant decreases occurred in the proportion of patients using drugs not labeled for migraine prophylaxis, nonopioid analgesics, nonsteroidal antiinflammatory drugs, and headache and migraine relief medications (p < 0.05). There was a 44.9% reduction in emergency room services, 53.2% reduction in migraine- related diagnostic procedures, and 57.1% reduction in migraine-related hospitalization days. Encounter claims for physicians' office visits did not change significantly.
CONCLUSION:
Migraine patients within commercially insured health plans incurred substantial resource use. Within six months following initiation of topiramate preventive therapy, reductions in acute migraine medication and medical resource use were observed among this population of migraine sufferers.
AuthorsAnthony L Feliu, Marcia F T Rupnow, Angela Blount, Stephen J Boccuzzi, James Vermilyea
JournalAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (Am J Health Syst Pharm) Vol. 64 Issue 14 Pg. 1483-91 (Jul 15 2007) ISSN: 1535-2900 [Electronic] England
PMID17617498 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Topiramate
  • Fructose
Topics
  • Adolescent
  • Adult
  • Aged
  • Cohort Studies
  • Drug Utilization
  • Emergency Service, Hospital (statistics & numerical data)
  • Female
  • Follow-Up Studies
  • Fructose (analogs & derivatives, therapeutic use)
  • Health Resources (statistics & numerical data)
  • Hospitalization
  • Humans
  • Male
  • Middle Aged
  • Migraine Disorders (diagnosis, drug therapy, epidemiology)
  • Topiramate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: